Current and future treatment options for polycythemia vera

Martin Griesshammer, Heinz Gisslinger, Ruben Mesa

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Patients with polycythemia vera (PV), a myeloproliferative neoplasm characterized by an elevated red blood cell mass, are at high risk of vascular and thrombotic complications and have reduced quality of life due to a substantial symptom burden that includes pruritus, fatigue, constitutional symptoms, microvascular disturbances, and bleeding. Conventional therapeutic options aim at reducing vascular and thrombotic risk, with low-dose aspirin and phlebotomy as first-line recommendations for patients at low risk of thrombotic events and cytoreductive therapy (usually hydroxyurea or interferon alpha) recommended for high-risk patients. However, long-term effective and well-tolerated treatments are still lacking. The discovery of mutations in Janus kinase 2 (JAK2) as the underlying molecular basis of PV has led to the development of several targeted therapies, including JAK inhibitors, and results from the first phase 3 clinical trial with a JAK inhibitor in PV are now available. Here, we review the current treatment landscape in PV, as well as therapies currently in development.

Original languageEnglish (US)
Pages (from-to)901-910
Number of pages10
JournalAnnals of Hematology
Volume94
Issue number6
DOIs
StatePublished - Jun 1 2015

    Fingerprint

Keywords

  • Hydroxyurea
  • Interferon
  • JAK inhibitor
  • Polycythemia vera
  • Ruxolitinib

ASJC Scopus subject areas

  • Hematology

Cite this